Targeting TROP-2 in Prostate Cancer Using Site-Specifically Radiolabeled IMMU-132 with ⁸⁹Zr via 3,4,3-LI(1,2-HOPO)
Nuklearmedizin - NuclearMedicine · 01.12.2025 · 64 (06) · 332-340
DOI: 10.1055/a-2723-3284 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nuklearmedizin - NuclearMedicine, erschienen am 01.12.2025. Verfasst von Syed Qaiser Shah und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Chemical Sciences, University of Peshawar Faculty of Life and Environmental Sciences, Peshawar, Pakistan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Zirconium, Radioisotopes, Antigens, Neoplasm. Die Arbeit nennt 22 Literaturangaben. Gefördert von: Higher Education Commission, Pakistan.
Abstract (Originalsprache)
To develop a site-specifically radiolabeled version of IMMU-132 (sacituzumab govitecan) using zirconium-89 (⁸⁹Zr) with the chelator 3,4,3-LI(1,2-HOPO) and evaluate its stability, specificity, and quantitative targeting ability in TROP-2–positive prostate cancer models. IMMU-132 was conjugated to 3,4,3-LI(1,2-HOPO)-maleimide and its integrity was confirmed by SDS-PAGE, SE-HPLC and mass spectrometry. Radiolabeling with ⁸⁹Zr was performed, and radiochemical yield and purity were measured. In vitro stability was assessed in human serum at 37 °C for 120 h. Binding affinity and specificity were evaluated using PC3 (TROP-2⁺) and A549 (TROP-2⁻) cells. Immunoreactivity was determined by Lindmo assay. In vivo PET imaging and ex vivo biodistribution were conducted in PC3-TROP-2⁺ xenograft-bearing mice. Radiolabeling with ⁸⁹Zr yielded 71.88 ± 0.21% with a radiochemical purity of 98.70 ± 0.55%. The radioconjugate maintained >90% stability in serum over 120 h. High-specific binding was observed in PC3 cells (Bmax ≈ 4750 CPM; Kd = 0.4 × 10⁶ cells/mL), with minimal uptake in A549 cells. The immunoreactive fraction was 88.10%. PET imaging revealed tumor-specific accumulation with a peak SUV mean of 5.8 ± 0.7 at 72 h post-injection. Biodistribution confirmed high tumor uptake (19.4 ± 2.1 %ID/g) and significantly reduced bone uptake (3.2 ± 0.5 %ID/g) compared to conventional ⁸⁹Zr-DFO tracers (p < 0.01). ⁸⁹Zr–IMMU-132–HOPO exhibits excellent in vivo stability, specificity, and selective accumulation in TROP-2–positive prostate tumors, while minimizing off-target bone uptake. These findings support its potential as a next-generation immuno-radiopharmaceutical for quantitative TROP-2 imaging and future theranostic applications in prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Chemical Sciences, University of Peshawar Faculty of Life and Environmental Sciences, Peshawar, Pakistan.
- Laboratory of Nano-Radiopharmacy, Nuclear Engineering Institute, Av. Helio de Almeida, 75, Ilha do Fundão, Rio de Janeiro, 21941906, Brazil, Brazilian Nuclear Energy Commission, Rio de Janeiro, Brazil.
- Faculty of Pharmacy Department of Radiopharmacy, Bornova, İzmir, Ege University, Izmir, Turkey.
- Nuclear Medicine Research Laboratory, Institute of Chemical Sciences University of Peshawar, Peshawar, 25120 K.P, Pakistan, University of Peshawar Faculty of Life and Environmental Sciences, Peshawar, Pakistan.
Förderung
- Higher Education Commission, Pakistan
Zitieren
APA
Shah, S. Q., Santos-Oliveira, R., Ozdemir, D., & Shirin, S. (2025). Targeting TROP-2 in Prostate Cancer Using Site-Specifically Radiolabeled IMMU-132 with ⁸⁹Zr via 3,4,3-LI(1,2-HOPO). Nuklearmedizin - NuclearMedicine, 64(06), 332-340. https://doi.org/10.1055/a-2723-3284
Vancouver
Shah SQ, Santos-Oliveira R, Ozdemir D, Shirin S. Targeting TROP-2 in Prostate Cancer Using Site-Specifically Radiolabeled IMMU-132 with ⁸⁹Zr via 3,4,3-LI(1,2-HOPO). Nuklearmedizin - NuclearMedicine. 2025;64(06):332-340. doi:10.1055/a-2723-3284
BibTeX
@article{Shah2025,
author = {Shah, Syed Qaiser and Santos-Oliveira, Ralph and Ozdemir, DeryaIlem and Shirin, Saba},
title = {Targeting TROP-2 in Prostate Cancer Using Site-Specifically Radiolabeled IMMU-132 with ⁸⁹Zr via 3,4,3-LI(1,2-HOPO)},
journal = {Nuklearmedizin - NuclearMedicine},
year = {2025},
volume = {64},
number = {06},
pages = {332--340},
doi = {10.1055/a-2723-3284}
}
EUVIMED